PMZ-1620 transiently alters the image of malignant but not benign solid tumors.
PMZ-1620 can be used to differentiate between a benign and a malignant tumor. In patients with breast cancer intravenous administration of PMZ-1620 shows a specific increase in tumor vessel diameter compared to baseline along with a corresponding decrease in resistive index. Patents granted in United States Patents No. 8,980,222, European Union (EP 05824775.0) and India (IP 243532).
Clinical stage – Phase III completed.
Tumor Diagnosis (PMZ-1620)